Targeted immunoconjugates
AssigneeRoche GlyeArt AG
InventorsEkkehard Mössner, Ralf Jörg Hosse, Pablo Umaña, Michela Silacci-Melkko
Life of this patent
Estimating the term…
Abstract
The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
Claims24
An immunoconjugate comprising:
- (a) at least a first single-chain effector moiety;
- and
- (b) a first and a second antigen binding moiety;
- wherein each of said first and second antigen binding moieties is a Fab molecule;
- wherein said first effector moiety shares an amino- or carboxy-terminal peptide bond with said first antigen binding moiety;
- wherein said second antigen binding moiety shares an amino- or carboxy-terminal peptide bond with either i) the first effector moiety, or ii) said first antigen binding moiety, and
- wherein said first effector moiety is not an Fc chain.
An immunoconjugate comprising a first single-chain effector moiety joined at its amino-terminal amino acid to one or more scFv molecules;
- and wherein said first single-chain effector moiety is joined at its carboxy-terminal amino acid to one or more scFv molecules, and is not an Fc chain.
Dependencies are inferred from the claim text.